Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 92 | ETA2023 | Next issue

45th Annual Meeting of the European Thyroid Association (ETA) 2023

45th Annual Meeting of the European Thyroid Association ETA 2023

Oral Session 10: Novel diagnostics in Thyroid cancer

ea0092op-10-01 | Oral Session 10: Novel diagnostics in Thyroid cancer | ETA2023

Identification of clinical and histopathological risk factors for radioactive iodine refractory disease in patients with follicular and hurthle cell thyroid carcinoma

Stegenga Merel , Oudijk Lindsey , Van Velsen Evert , Medici Marco , Peeters Robin , Edward Visser W. , van Kemenade Folkert

Introduction: Historically, treatment of follicular thyroid carcinoma (FTC) and oncocytic thyroid carcinoma (OTC) is based on thyroidectomy followed by radioiodine (RAI) therapy. Both tumor types have a good prognosis (10-year survival 80-94%), but this changes significantly once RAI-refractory disease occurs (median 3.5 years), which limits further treatment possibilities. The main risk factors for developing RAI-refractory disease in FTC and OTC are unknown. Our aim was to i...

ea0092op-10-02 | Oral Session 10: Novel diagnostics in Thyroid cancer | ETA2023

Role of the telomere abnormalities and chromosome fragility on the risk of second malignant tumor in papillary thyroid cancer patients

Valerio Laura , Mattii Elisa , Cantara Silvia , Cartocci Alessandra , Maino Fabio , Grazia Castagna Maria

Objectives: Genomic instability play a role in cancer development through different mechanisms including chromosome fragility and in particular the altered telomere length (TL). Previous studies showed that the presence of short telomeres in the blood was associated with development of sporadic head and neck, bladder, lung, renal and breast cancer. In thyroid cancer, has been demonstrated that familial form of papillary thyroid cancer (FPTC) has shorter telomeres in blood leuk...

ea0092op-10-03 | Oral Session 10: Novel diagnostics in Thyroid cancer | ETA2023

KI67 proliferative index, but not mitotic count and necrosis, is a prognostic factor in patients with medullary thyroid cancer: a single-center retrospective analysis according to the 2022 who pathological classification

Prinzi Antonio , Bosco Agata , Mirone Alessandro , Tumino Dario , Di Benedetto Guenda , Gambero Federica , Bartoloni Giovanni , Frasca Francesco , Belfiore Antonino , Malandrino Pasqualino

Background: The 2022 WHO Classification of Endocrine and Neuroendocrine Tumors has introduced, as other neuroendocrine neoplasms, new pathological features to classify medullary thyroid carcinoma (MTC) in low/high grade. However, whether it can be reliable in clinical practice should be confirm by further studies.Aim: To verify the predictive value of the 2022 WHO grading system in patients with MTC.Materials and Methods: Tumor tis...

ea0092op-10-04 | Oral Session 10: Novel diagnostics in Thyroid cancer | ETA2023

Improvement in neck ultrasound report quality following implementation of ETA guidelines for postoperative cervical ultrasound for thyroid cancer follow-up, a prospective population study

Wu Jiahui , Yang Hu Xun , Seal Paula , Amin Parthiv , Paschke Ralf

Objective: We prospectively evaluated the quality of postoperative neck ultrasound (POU) for thyroid cancer patients in our healthcare region after the implementation of European Thyroid Association (ETA) guideline-based POU assessment with one radiology group in 2018.Methods: Our analysis involved 672 differentiated thyroid cancer (DTC) patients treated at our center between April 1, 2017, and March 1, 2023. POU report quality was compared between radio...

ea0092op-10-05 | Oral Session 10: Novel diagnostics in Thyroid cancer | ETA2023

Hypothyroidism and the risk of cancer: a danish register-based long-term follow-up study

Riis Thea , Neergaard Pettersen Frida , Joop Bonnema Steen , Brix Thomas , Folkestad Lars

Objective: Globally, cancer is one of the leading causes of death. Therefore, identification of risk factors is of paramount interest. Whether thyroid dysfunction is a cancer risk factor is currently being debated. The aim of this study was to evaluate the risk of cancer in patients diagnosed with hypothyroidism.Methods: This is a register-based nationwide cohort study of individuals diagnosed with hypothyroidism referred to Danish hospitals (followed fr...